Table 1.

Clinical and demographic characteristics for cohorts 1, 2, and 3/cohort 1 (n = 11) diagnosis and age.

Diagnosis	Sex (male/female)	Age (mean ± SD)
COHORT 1
SZ	2/3	53 ± 7
Control*	2/4	57 ± 27
Total	4/7
COHORT 2
BD	9/3	50 ± 17
MDD	11/4	51 ± 15
SZ	11/3	44 ± 10
Control	29/6	53 ± 12
Total	60/16
COHORT 3
BD	3/1	57 ± 8
MDD	4/1	41 ± 14
SZ	2/2	41 ± 9
Control*	7/3	52 ± 23
Total	16/7

The 4,977 bp mtDNA common deletion percentage was measured in 11 brain regions. Cohort 2 was used in the assay for mtDNA common deletion (4,977 bp) of 76 DLPFC samples. Cohort 3 was used for Illumina re-sequencing of mtDNA in 23 DLPFC samples. Five control subjects were completely re-sequenced in 11 brain regions, three subjects also had blood re-sequenced (ages 53, 64, and 103 years old).

*Five overlapping control subjects from Cohort 1 shown in Table S1 in Supplementary Material were included in this cohort.